RE: Nov 11 Versant Report BUY $ 14.50.
Al............it isn't the Gastrin that is Pegylated in this Trial it is Lilly's GLP1 that is......or PEGylated GLP1
. You just read it wrong ..........Note the Hyphen between Gastrin and Pegylation GLP1......... It is a once weekly GLP1 that has longer acting properties due to the pegylation........Lilly is also testing a Protein Fusion GLP1 or GLP1 fc but it is not at this time combo'd with TT223. Heres a slide showing the two different GLP1's.
https://www.glucagon.com/pdfs/LillyDec112008.pdf
A quick check on Clinical Trial dot Gov will confirm all this. Note that this Trial TT223 is Combo'd with LY2428757
https://clinicaltrials.gov/ct2/show/NCT00853151 which is the PEG.
The TT223 being used for this Trial is of course Modified Gastrin but
IS NOT the newer Long Acting Versions that Dr. Cruz mentioned last CC.
The newer versions Have 4 month and 8 month Half Lives and are Modified Gastrin made longer acting by a couple of different methods. According to the Patents One method is by taking Modified Gastrin and Conjugating it with PEG20,000.........the other long acting gastrin is made by taking Modified Gastrin and Conjugating it to HSA ( Human Serum Albumin). It is not made clear in the patents which is the longer acting of the two. At this point it doesn't matter though. These are for future use or testing........... there has to be long term Tox studies done and the Human Safety Trials will need to be done according to Dr. Cruz.
Thanks for the Versant. I see Dougs still calling it a Monotherapy Trial which IT IS NOT.........It is a Trial for TT223 and patients currently treated with Metformin and/or Thiazolidinedione. That is not a Monotherapy Trial...........a monotherapy Trial would be TT223 Alone without ANY other med's,,,,
.
.